Tarenflurbil

Drug Profile

Tarenflurbil

Alternative Names: R-Flurbiprofen; E-7869; Flurizan; MPC-7869; TMP-001; TruNoc

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator Loma Linda University Medical Center
  • Developer Fraunhofer Institute for Molecular Biology and Applied Ecology; Horizon Pharma AG; Myriad Pharmaceuticals
  • Class Antidementias; Antineoplastics; Biphenyl compounds; Propionic acids; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase modulators; NF-kappa B inhibitors; Transcription factor AP-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • Discontinued Alzheimer's disease; Inflammation; Pain; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 16 Jul 2015 Phase-II clinical trials in Multiple sclerosis (Relapsing, remitting) in Germany (PO) (EudraCT2014-004483-38)
  • 23 Mar 2012 Discontinued - Preclinical for Inflammation in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top